APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ertapenem Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ertapenem Injection Market Outlook and Growth Opportunities 2026

20 December 2025195 pages

Choose your research edition.

Industry ResearchErtapenem Injection Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Ertapenem Injection Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Ertapenem Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ertapenem Injection Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Ertapenem Injection Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Ertapenem Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ertapenem Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ertapenem Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ertapenem Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ertapenem Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ertapenem Injection market include Merck, Aurobindo Pharma, Endo and ACS Dobfar, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ertapenem Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ertapenem Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ertapenem Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ertapenem Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Ertapenem Injection Segment by Company

Merck

Aurobindo Pharma

Endo

ACS Dobfar

Ertapenem Injection Segment by Type

1g/Vial

Others

Ertapenem Injection Segment by Application

Adult

Pediatric

Ertapenem Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Ertapenem Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Ertapenem Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ertapenem Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Ertapenem Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ertapenem Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ertapenem Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ertapenem Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ertapenem Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ertapenem Injection industry.

Chapter 3: Detailed analysis of Ertapenem Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Ertapenem Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Ertapenem Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ertapenem Injection Industry Trends Table 2. Ertapenem Injection Industry Drivers Table 3. Ertapenem Injection Industry Opportunities and Challenges Table 4. Ertapenem Injection Industry Restraints Table 5. Global Ertapenem Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ertapenem Injection Revenue Share by Company (2021-2026) Table 7. Global Ertapenem Injection Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Ertapenem Injection Sales Volume Share by Company (2021-2026) Table 9. Global Ertapenem Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Ertapenem Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Ertapenem Injection Key Company Manufacturing Base & Headquarters Table 12. Global Ertapenem Injection Company, Product Type & Application Table 13. Global Ertapenem Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Ertapenem Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 1g/Vial Table 18. Significant Companies of Others Table 19. Global Ertapenem Injection Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Ertapenem Injection Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Ertapenem Injection Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Ertapenem Injection Sales Volume Share by Type (2021-2026) Table 23. Global Ertapenem Injection Sales Volume Share by Type (2027-2032) Table 24. Global Ertapenem Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Ertapenem Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Ertapenem Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Ertapenem Injection Sales Value Share by Type (2021-2026) Table 28. Global Ertapenem Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adult Table 30. Significant Companies of Pediatric Table 31. Global Ertapenem Injection Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Ertapenem Injection Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Ertapenem Injection Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Ertapenem Injection Sales Volume Share by Application (2021-2026) Table 35. Global Ertapenem Injection Sales Volume Share by Application (2027-2032) Table 36. Global Ertapenem Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Ertapenem Injection Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Ertapenem Injection Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Ertapenem Injection Sales Value Share by Application (2021-2026) Table 40. Global Ertapenem Injection Sales Value Share by Application (2027-2032) Table 41. Global Ertapenem Injection Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Ertapenem Injection Sales by Region (2021-2026) & (W Units) Table 43. Global Ertapenem Injection Sales Market Share by Region (2021-2026) Table 44. Global Ertapenem Injection Sales by Region (2027-2032) & (W Units) Table 45. Global Ertapenem Injection Sales Market Share by Region (2027-2032) Table 46. Global Ertapenem Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Ertapenem Injection Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Ertapenem Injection Sales Value Share by Region (2021-2026) Table 49. Global Ertapenem Injection Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Ertapenem Injection Sales Value Share by Region (2027-2032) Table 51. Global Ertapenem Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Ertapenem Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Ertapenem Injection Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Ertapenem Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Ertapenem Injection Sales by Country (2021-2026) & (W Units) Table 56. Global Ertapenem Injection Sales Market Share by Country (2021-2026) Table 57. Global Ertapenem Injection Sales by Country (2027-2032) & (W Units) Table 58. Global Ertapenem Injection Sales Market Share by Country (2027-2032) Table 59. Global Ertapenem Injection Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Ertapenem Injection Sales Value Market Share by Country (2021-2026) Table 61. Global Ertapenem Injection Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Ertapenem Injection Sales Value Market Share by Country (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Ertapenem Injection Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Merck Ertapenem Injection Product Portfolio Table 67. Merck Recent Development Table 68. Aurobindo Pharma Company Information Table 69. Aurobindo Pharma Business Overview Table 70. Aurobindo Pharma Ertapenem Injection Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Aurobindo Pharma Ertapenem Injection Product Portfolio Table 72. Aurobindo Pharma Recent Development Table 73. Endo Company Information Table 74. Endo Business Overview Table 75. Endo Ertapenem Injection Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Endo Ertapenem Injection Product Portfolio Table 77. Endo Recent Development Table 78. ACS Dobfar Company Information Table 79. ACS Dobfar Business Overview Table 80. ACS Dobfar Ertapenem Injection Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. ACS Dobfar Ertapenem Injection Product Portfolio Table 82. ACS Dobfar Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Ertapenem Injection Distributors List Table 86. Ertapenem Injection Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Ertapenem Injection Product Image Figure 2. Global Ertapenem Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ertapenem Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Ertapenem Injection Sales (2021-2032) & (W Units) Figure 5. Global Ertapenem Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Ertapenem Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 1g/Vial Image Figure 10. Others Image Figure 11. Global Ertapenem Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Ertapenem Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Ertapenem Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Ertapenem Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Ertapenem Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Ertapenem Injection Sales Value Share by Type (2021-2032) Figure 17. Adult Image Figure 18. Pediatric Image Figure 19. Global Ertapenem Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Ertapenem Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Ertapenem Injection Sales Volume Share by Application (2021-2032) Figure 22. Global Ertapenem Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Ertapenem Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Ertapenem Injection Sales Value Share by Application (2021-2032) Figure 25. Global Ertapenem Injection Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Ertapenem Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Ertapenem Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Ertapenem Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Ertapenem Injection Sales Value (2021-2032) & (US$ Million) Figure 30. North America Ertapenem Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Ertapenem Injection Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Ertapenem Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Ertapenem Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Ertapenem Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Ertapenem Injection Sales Value (2021-2032) & (US$ Million) Figure 36. South America Ertapenem Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Ertapenem Injection Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Ertapenem Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Ertapenem Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Ertapenem Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Ertapenem Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Ertapenem Injection Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Ertapenem Injection Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 1g/Vial
  • Others
Applications
  • Adult
  • Pediatric
Companies covered
  • Merck
  • Aurobindo Pharma
  • Endo
  • ACS Dobfar

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ertapenem Injection Sales Value (2021-2032)
  4. 1.2.2 Global Ertapenem Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Ertapenem Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Ertapenem Injection Market Dynamics
  1. 2.1 Ertapenem Injection Industry Trends
  2. 2.2 Ertapenem Injection Industry Drivers
  3. 2.3 Ertapenem Injection Industry Opportunities and Challenges
  4. 2.4 Ertapenem Injection Industry Restraints
3 Ertapenem Injection Market by Company
  1. 3.1 Global Ertapenem Injection Company Revenue Ranking in 2025
  2. 3.2 Global Ertapenem Injection Revenue by Company (2021-2026)
  3. 3.3 Global Ertapenem Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Ertapenem Injection Average Price by Company (2021-2026)
  5. 3.5 Global Ertapenem Injection Company Ranking (2024-2026)
  6. 3.6 Global Ertapenem Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Ertapenem Injection Company Product Type and Application
  8. 3.8 Global Ertapenem Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Ertapenem Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Ertapenem Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Ertapenem Injection Market by Type
  1. 4.1 Ertapenem Injection Type Introduction
  2. 4.1.1 1g/Vial
  3. 4.1.2 Others
  4. 4.2 Global Ertapenem Injection Sales Volume by Type
  5. 4.2.1 Global Ertapenem Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Ertapenem Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Ertapenem Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Ertapenem Injection Sales Value by Type
  9. 4.3.1 Global Ertapenem Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Ertapenem Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Ertapenem Injection Sales Value Share by Type (2021-2032)
5 Ertapenem Injection Market by Application
  1. 5.1 Ertapenem Injection Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global Ertapenem Injection Sales Volume by Application
  5. 5.2.1 Global Ertapenem Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Ertapenem Injection Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Ertapenem Injection Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Ertapenem Injection Sales Value by Application
  9. 5.3.1 Global Ertapenem Injection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Ertapenem Injection Sales Value by Application (2021-2032)
  11. 5.3.3 Global Ertapenem Injection Sales Value Share by Application (2021-2032)
6 Ertapenem Injection Regional Sales and Value Analysis
  1. 6.1 Global Ertapenem Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ertapenem Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Ertapenem Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Ertapenem Injection Sales by Region (2027-2032)
  5. 6.3 Global Ertapenem Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Ertapenem Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Ertapenem Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Ertapenem Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Ertapenem Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Ertapenem Injection Sales Value (2021-2032)
  12. 6.6.2 North America Ertapenem Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Ertapenem Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Ertapenem Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Ertapenem Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Ertapenem Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Ertapenem Injection Sales Value (2021-2032)
  21. 6.9.2 South America Ertapenem Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Ertapenem Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Ertapenem Injection Sales Value Share by Country, 2025 VS 2032
7 Ertapenem Injection Country-level Sales and Value Analysis
  1. 7.1 Global Ertapenem Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ertapenem Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Ertapenem Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Ertapenem Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Ertapenem Injection Sales by Country (2027-2032)
  6. 7.4 Global Ertapenem Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Ertapenem Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Ertapenem Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Ertapenem Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Ertapenem Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Ertapenem Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Ertapenem Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Ertapenem Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Ertapenem Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Ertapenem Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Ertapenem Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Ertapenem Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Ertapenem Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Ertapenem Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Ertapenem Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Ertapenem Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Ertapenem Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Ertapenem Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Ertapenem Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Ertapenem Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Ertapenem Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Ertapenem Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Ertapenem Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Ertapenem Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Ertapenem Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Ertapenem Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Ertapenem Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Ertapenem Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Ertapenem Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Ertapenem Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Ertapenem Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Ertapenem Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Ertapenem Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Ertapenem Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Ertapenem Injection Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Aurobindo Pharma
  8. 8.2.1 Aurobindo Pharma Company Information
  9. 8.2.2 Aurobindo Pharma Business Overview
  10. 8.2.3 Aurobindo Pharma Ertapenem Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aurobindo Pharma Ertapenem Injection Product Portfolio
  12. 8.2.5 Aurobindo Pharma Recent Developments
  13. 8.3 Endo
  14. 8.3.1 Endo Company Information
  15. 8.3.2 Endo Business Overview
  16. 8.3.3 Endo Ertapenem Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Endo Ertapenem Injection Product Portfolio
  18. 8.3.5 Endo Recent Developments
  19. 8.4 ACS Dobfar
  20. 8.4.1 ACS Dobfar Company Information
  21. 8.4.2 ACS Dobfar Business Overview
  22. 8.4.3 ACS Dobfar Ertapenem Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ACS Dobfar Ertapenem Injection Product Portfolio
  24. 8.4.5 ACS Dobfar Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ertapenem Injection Value Chain Analysis
  2. 9.1.1 Ertapenem Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ertapenem Injection Sales Mode & Process
  6. 9.2 Ertapenem Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ertapenem Injection Distributors
  9. 9.2.3 Ertapenem Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst